Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Project CBD

OCTOBER 26, 2023

I advise my patients to stop using cannabis for 36 to 48 hours prior to chemotherapy and to start again 36 to 48 hours after their session. Phase 2 is the first study level conducted on patients with the disease for which the drug is intended and determines whether it is safe and effective. mg of THC and 30 mg of CBD.

Research and Development 343

Research and Development Cannabinoids Terpenes Pharmaceutical 343

CannaMD

MARCH 8, 2020

In January of 2020, the Journal of the American College of Cardiology published a review titled Marijuana Use in Patients With Cardiovascular Disease. Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Marijuana users with cardiovascular disease.

Patients 79

Patients Marijuana Research and Development Clinical Trials 79

The Cannigma

OCTOBER 14, 2022

Recreational cannabis is not legal, despite a 2019 citizen’s initiative that called for legalization. In 2019 the Parliament approved a citizen’s proposal to regulate recreational use of cannabis, but backtracked in March 2020 , saying they would wait to follow the lead of Italy. Is weed legal in San Marino? Is CBD legal in San Marino?

Law 56

Law Clinical Trials Research and Development Recreational 56

Cannabis Law Report

AUGUST 19, 2019

There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government.

Medicine 45

Medicine Patients Clinical Trials Access 45

Project CBD

MAY 3, 2023

Dr. Goldstein has treated thousands of patients with medical cannabis. She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. I have used it in some of my patients with autism. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

DECEMBER 9, 2021

(the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N , N -Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services. Christopher J.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 2, 2022

The double-blind, randomised, placebo-controlled clinical trial took place over two years between 2017 and 2019 at the Center for Medicinal Cannabis Research at the University of California. As many patients use cannabis-based medicines to aid with sleep, the current detection window is of significant concern.

Medicine 52

Medicine Clinical Trials Consumption Sleep 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA).

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek’s Seed to Patient business model combines cutting edge cultivation expertise and world class manufacturing practices to deliver high quality medicinal cannabis oil formulations and medicinal strains of dried flowers at a significantly lower cost to patients and retailers.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

NORML

JANUARY 28, 2019

The National Center for Biotechnology Information has summarized a group of FDA approved randomized clinical trials, finding evidence for cannabis as medicine. Sadly, it seems Stivers already has an answer for would-be medical cannabis patients. Have a bourbon,” he told the Courier-Journal. 8 – state Rep.

Data 189

Data Clinical Trials Chronic Pain Medicine 189

Cannabis Law Report

MARCH 21, 2019

With so much random information being thrown around the internet, it can be very difficult to differentiate what is true and what is false. Georgia only allows patients diagnosed with cancer, ALS, seizures, and other serious medical conditions to legally possess CBD. In 2014, Mississippi legalized CBD for epileptic patients.

State Laws 55

State Laws Law CBD Legalization 55

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. Physicians will likely be caring for patients who are using cannabis regardless of their own beliefs about it.

Education 101

Education Clinical Trials Medicine Policy 101

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. In this program, we extend our experience and expertise to healthcare professionals, in order to support them to meet the needs of their patients.”

Programs 108

Programs Research and Development Education Treatment 108

The Cannigma

MARCH 7, 2022

In a 2019 animal study, CBN isolate was reported to relieve musculoskeletal pain. What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Denver, Colorado was the first jurisdiction to decriminalize the use of psilocybin via ballot initiative in May 2019. 10; 312.80-88;

Law 105

Law Therapy Clinical Trials Research and Development 105

Peninsula Alternative Health

MAY 15, 2019

With clinical research developing rapidly in Israel and with the use of innovative technology we hope to have this information in the near future. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Project CBD

AUGUST 6, 2019

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Results highlight the need for expanded patient access to CBD products.”.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. Adams, CEO.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

AUGUST 30, 2019

Americans for Safe Access released its 2018-2019 State-of-the-State report examining state laws and regulations surrounding Patient Rights and Civil Protection from Discrimination, Access to Medicine, Ease of Navigation, Functionality of the Programs, and Consumer Safety and Provider Requirements. billion by 2024. Medical/Health.

Banking 45

Banking Research and Development Legislation Programs 45

Puff Puff Post

JULY 8, 2019

July 8, 2019 /Canna Newswire/ – The Colorado-based Canna Research Group developed The Athlete Pain, Exercise, and Cannabis Experience (PEACE) Survey study for active adults to look beyond the stigma of cannabis use in athletes. Our results need to be replicated in larger studies and clinical trials. BOULDER, Colo.

Chronic Pain 109

Chronic Pain Research and Development Clinical Trials THC 109

Puff Puff Post

JULY 8, 2019

July 8, 2019 /Canna Newswire/ – The Colorado-based Canna Research Group developed The Athlete Pain, Exercise, and Cannabis Experience (PEACE) Survey study for active adults to look beyond the stigma of cannabis use in athletes. Our results need to be replicated in larger studies and clinical trials. BOULDER, Colo.

Chronic Pain 108

Chronic Pain Research and Development Clinical Trials THC 108

Cannabis Law Report

JULY 6, 2021

In 2019, Dr. Johnson received the R. Johnson, DSc, MD, MPhil, FRCPsych said, “I am pleased to join the Ehave Medical Advisory Board and look forward to working towards bringing psychedelic-assisted therapies to patients experiencing substance use issues. Brinkley Smithers award from the American Association of Addiction Medicine.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Project CBD

AUGUST 6, 2019

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Results highlight the need for expanded patient access to CBD products.”.

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

The Cannigma

JANUARY 13, 2023

The fact that migraine is now ranked as the second leading cause of years lived with disability illustrates the magnitude of the negative impact of the disease to patients and their ability to function normally. A 2019 retrospective review of 316 patients found that medical cannabis improved the experience of 88.3%

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

MAY 29, 2022

In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. and Seattle, among other municipalities.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Simon Makin, Behind the Buzz: How Ketamine Changes the Depressed Patient’s Brain , SCI. 12, 2019), [link] [ [link] ]. 10, 2019), [link] [ [link] ]. 26, 2019, 4:07 PM), [link] [ [link] ].

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

AUGUST 2, 2021

The Real World Evidence (RWE) collected will inform scientific understanding on dosing, usage patterns, user characteristics, effectiveness across conditions, and predictors and modifiers of treatment response. “We Patients are unclear on what product to choose and healthcare providers don’t yet have the data to counsel on proper dosage.”.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

JULY 15, 2019

Law 33/2018 set the framework for the regulation of the use of cannabis-based medicinal products, preparations and substances that would effectively allow Portuguese patients to access medical cannabis What really has changed during the last year? July 18 marks the first anniversary of the Portuguese medical cannabis law.

Medicine 40

Medicine Clinical Trials Patients Access 40

The Blunt Truth

AUGUST 13, 2019

In March of 2019, the FDA established a Working Group to determine the possible legislative pathways to regulate CBD. On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

JUNE 25, 2021

In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. For more information about this report visit [link]. Varian Medical Systems. Merck & Co.

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

Cannabis Law Report

NOVEMBER 24, 2019

NICE guideline [NG144] Published date: November 2019. Finding more information and committee details. People have the right to be involved in discussions and make informed decisions about their care, as described in your care. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JULY 4, 2019

The manuscript is part of EMMAC’s collaboration with Imperial College London, forged to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40